Department of Ophthalmology, Clínica Universidad de Navarra, Apartado 4209, 31080 Pamplona, Spain.
Regen Med. 2013 Mar;8(2):183-95. doi: 10.2217/rme.13.11.
Penetrating keratoplasty has previously been the only surgical treatment for patients with corneal endothelial disorders. Recently, posterior lamellar keratoplasty has become a viable and less aggressive alternative technique. However, both transplantation techniques have disadvantages, such as non-immunologic graft failure, allograft endothelial rejection or a global shortage of donor corneas. Over the past few years, several groups have established methods for the isolation, preservation, in vitro cultivation, transplantation, and in vivo stimulation of human corneal endothelial cells in animal models. It is hoped that these new strategies will allow the treatment of more than one patient with one donor cornea, performing autologous corneal endothelium transplantation from a surgical biopsy sample, or stimulating the growth of corneal endothelial cells in vivo. However, several aspects need to be addressed before commencing clinical trials.
穿透性角膜移植术以前是治疗角膜内皮疾病患者的唯一手术方法。最近,后板层角膜移植术已成为一种可行且侵袭性较小的替代技术。然而,这两种移植技术都有缺点,如非免疫性移植物失功、同种异体角膜内皮排斥反应或供体角膜的全球短缺。在过去的几年中,有几个研究小组已经在动物模型中建立了分离、保存、体外培养、移植和体内刺激人角膜内皮细胞的方法。人们希望这些新策略将允许使用一个供体角膜为不止一个患者进行治疗,通过手术活检样本进行自体角膜内皮移植,或在体内刺激角膜内皮细胞的生长。然而,在开始临床试验之前,还需要解决几个方面的问题。